Statement on the recommended use of monoclonal anti-RSV antibody (palivizumab).
about
Respiratory infections in children up to two years of age on prophylaxis with palivizumab.Respiratory syncytial virus: pervasive yet evasivePalivizumab use among children with congenital heart disease in Quebec: Impact of Canadian guidelines on clinical practice.Optimizing the delivery and use of a new monoclonal antibody in children with congenital heart disease: a successful provincial respiratory syncytial virus prophylaxis program.Prophylaxis of respiratory syncytial virus in Canada in 2003.Respiratory syncytial virus and palivizumab: Where are we in 2014?Respiratory syncytial virus immunoprophylaxis in high-risk infants and development of childhood asthma.
P2860
Q34279488-058671BB-561B-4B7D-8233-9BB72CF7C75FQ35161749-924F19AD-B9AA-4821-9B33-C4AD7CDD4FA9Q36731851-79B28AA3-5216-4A4C-9462-F13B48A884D6Q36814797-89E59996-38F8-41C6-B4BB-01848E6B1437Q37481321-D9C57F22-0BA7-4AC5-BAB5-511FE775C3A9Q37632426-CA284505-567E-4D4E-94B8-21EDF2E79EF0Q40664195-D68F4D68-471E-41A7-A829-BCAF6ED4D64F
P2860
Statement on the recommended use of monoclonal anti-RSV antibody (palivizumab).
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
2003年學術文章
@zh-hant
name
Statement on the recommended use of monoclonal anti-RSV antibody (palivizumab).
@en
Statement on the recommended use of monoclonal anti-RSV antibody
@nl
type
label
Statement on the recommended use of monoclonal anti-RSV antibody (palivizumab).
@en
Statement on the recommended use of monoclonal anti-RSV antibody
@nl
prefLabel
Statement on the recommended use of monoclonal anti-RSV antibody (palivizumab).
@en
Statement on the recommended use of monoclonal anti-RSV antibody
@nl
P1476
Statement on the recommended use of monoclonal anti-RSV antibody (palivizumab).
@en
P2093
National Advisory Committee on Immunization
P577
2003-09-01T00:00:00Z